Gyre Therapeutics (GYRE) filed a shelf registration statement with the US Securities and Exchange Commission Thursday covering the potential sale of up to $150 million of its securities from time to time in one or more offerings.
The statement covers common and preferred shares, debt securities, warrants, and units.
The company said it will use the net proceeds generated from any securities sale for development, manufacturing, and scale-up, as well as for working capital and general corporate purposes, among other things.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。